Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
VMD Stock Summary
Top 10 Correlated ETFs
VMD
In the News
Viemed Healthcare Announces Date and Time for Conference Call
LAFAYETTE, La., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will host its Year End Conference Call on Thursday, March 7, 2024 at 11:00 a.m. ET.
Viemed Healthcare to Present at Stifel 2023 Healthcare Conference
LAFAYETTE, La., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will participate in the Stifel 2023 Healthcare Conference on November 15, 2023, in New York, New York at the Lotte New York Palace Hotel, located at 455 Madison Ave.
Viemed Healthcare, Inc. (VMD) Q3 2023 Earnings Call Transcript
Viemed Healthcare, Inc. (NASDAQ:VMD ) Q3 2023 Earnings Conference Call November 2, 2023 11:00 AM ET Company Participants Todd Zehnder - COO Casey Hoyt - CEO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Doug Cooper - Beacon Securities Limited Michael Freeman - Raymond James Operator Greetings, and welcome to Viemed's 3Q 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
Viemed Healthcare to Participate in Upcoming Investor Conferences
LAFAYETTE, La., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will participate in the following upcoming investor conferences:
3 Undervalued Small-Cap Stocks for Your Labor Day Watchlist
One reason August can be volatile is that trading volume is down. Although news items may stir up activity, there's a difference between activity and productive action that really moves markets.
The 7 Most Undervalued Stocks Under $10 to Buy Now: August 2023
If you're hurting from inflation – and there's a good chance you are – these stocks to buy under $10 might offer what you're looking for. To start, these “cheap” investment ideas offer perceived affordability, which goes a long way.
Viemed Healthcare: Qualified Growth Company, HMP Transaction Accretive To Value
Viemed Healthcare's equity stock has consolidated by ~20% after a strong rally, but the company's economic outlook remains unchanged. The acquisition of HMP has added potential value to VMD, expanding its geographical reach and bringing revenue synergies. Viemed Healthcare's Q2 earnings showed strong growth, with sales up 31% YoY, and the company expects continued expansion in FY'23 and FY'24.
Viemed Healthcare Announces Date and Time for Conference Call
LAFAYETTE, La., July 25, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will host its Quarterly Conference Call on Thursday, August 10, 2023 at 11:00 a.m. ET.
Viemed Healthcare: Superb Growth Expectations, Reiterate Buy
Viemed Healthcare collected another quarter of sequential and YoY sales growth. Investors have revised expectations for the company and added $273mm in market cap off March 2022 lows.
Viemed Healthcare, Inc. (VMD) Misses Q1 Earnings Estimates
Viemed Healthcare, Inc. (VMD) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.04 per share a year ago.
VMD Financial details
VMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.02 | 3.39 | 2.96 | 3.59 | 4.62 | |
Net income per share | 0.21 | 0.81 | 0.23 | 0.16 | 0.25 | |
Operating cash flow per share | 0.48 | 0.91 | 0.57 | 0.72 | 1.14 | |
Free cash flow per share | 0.14 | 0.57 | 0.07 | 0.13 | 0.48 | |
Cash per share | 0.34 | 0.8 | 0.72 | 0.39 | 0.32 | |
Book value per share | 1.1 | 2.11 | 2.4 | 2.51 | 2.81 | |
Tangible book value per share | 1.1 | 2.11 | 2.4 | 2.51 | 2.06 | |
Share holders equity per share | 1.1 | 2.11 | 2.4 | 2.51 | 2.81 | |
Interest debt per share | 0.5 | 0.3 | 0.17 | 0.02 | 0.21 | |
Market cap | 246.43M | 300.65M | 206.14M | 292.23M | 316.97M | |
Enterprise value | 252.59M | 280.8M | 184.25M | 276.01M | 314.47M | |
P/E ratio | 28.91 | 9.54 | 22.59 | 46.97 | 30.95 | |
Price to sales ratio | 3.07 | 2.29 | 1.76 | 2.1 | 1.7 | |
POCF ratio | 12.91 | 8.56 | 9.16 | 10.53 | 6.88 | |
PFCF ratio | 43.22 | 13.63 | 74.93 | 60.25 | 16.28 | |
P/B Ratio | 5.64 | 3.68 | 2.17 | 3.01 | 2.8 | |
PTB ratio | 5.64 | 3.68 | 2.17 | 3.01 | 2.8 | |
EV to sales | 3.15 | 2.14 | 1.57 | 1.99 | 1.69 | |
Enterprise value over EBITDA | 16.17 | 8.23 | 7.75 | 11.23 | 8.26 | |
EV to operating cash flow | 13.23 | 8 | 8.19 | 9.95 | 6.83 | |
EV to free cash flow | 44.3 | 12.73 | 66.98 | 56.91 | 16.15 | |
Earnings yield | 0.03 | 0.1 | 0.04 | 0.02 | 0.03 | |
Free cash flow yield | 0.02 | 0.07 | 0.01 | 0.02 | 0.06 | |
Debt to equity | 0.45 | 0.14 | 0.07 | 0.01 | 0.07 | |
Debt to assets | 0.24 | 0.1 | 0.06 | 0.01 | 0.05 | |
Net debt to EBITDA | 0.39 | -0.58 | -0.92 | -0.66 | -0.07 | |
Current ratio | 1.07 | 2.05 | 2.66 | 2.11 | 1.19 | |
Interest coverage | 27.86 | 52.61 | 36.42 | 41.89 | 36.59 | |
Income quality | 2.24 | 1.11 | 2.46 | 4.46 | 4.41 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.05 | 0 | 0.01 | 0.04 | 0.04 | |
Sales general and administrative to revenue | 0.56 | 0.44 | 0.51 | 0.53 | 0.5 | |
Research and developement to revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.2 | |
Capex to operating cash flow | -0.7 | -0.37 | -0.88 | -0.83 | -0.58 | |
Capex to revenue | -0.17 | -0.1 | -0.17 | -0.16 | -0.14 | |
Capex to depreciation | -2.09 | -1.36 | -1.75 | -1.47 | -1.19 | |
Stock based compensation to revenue | 0.05 | 0.04 | 0.04 | 0.04 | 0.03 | |
Graham number | 2.3 | 6.21 | 3.53 | 3.02 | 4 | |
ROIC | 0.12 | 0.33 | 0.08 | 0.06 | 0.09 | |
Return on tangible assets | 0.1 | 0.28 | 0.08 | 0.05 | 0.08 | |
Graham Net | -0.41 | 0.27 | 0.44 | 0.21 | -0.3 | |
Working capital | 1.9M | 24.16M | 29.5M | 20.88M | 6.21M | |
Tangible asset value | 43.7M | 81.69M | 94.82M | 97.09M | 82.98M | |
Net current asset value | -11.09M | 16.31M | 24.17M | 19.79M | -2.62M | |
Invested capital | 0.45 | 0.14 | 0.07 | 0.01 | 0.07 | |
Average receivables | 10.19M | 11.95M | 13.54M | 15.06M | 16.88M | |
Average payables | 5.29M | 3.4M | 2.67M | 2.94M | 3.4M | |
Average inventory | 2.12M | 1.84M | 2.38M | 3.02M | 4.09M | |
Days sales outstanding | 52.46 | 34.39 | 45.88 | 40.5 | 35.95 | |
Days payables outstanding | 70.74 | 14.94 | 27.08 | 17.86 | 20.81 | |
Days of inventory on hand | 20.47 | 16.47 | 20.54 | 24.09 | 23.04 | |
Receivables turnover | 6.96 | 10.61 | 7.95 | 9.01 | 10.15 | |
Payables turnover | 5.16 | 24.43 | 13.48 | 20.43 | 17.54 | |
Inventory turnover | 17.83 | 22.16 | 17.77 | 15.15 | 15.84 | |
ROE | 0.2 | 0.39 | 0.1 | 0.06 | 0.09 | |
Capex per share | -0.34 | -0.34 | -0.5 | -0.59 | -0.66 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.99 | 1.04 | 1.12 | 1.29 | 1.35 | |
Net income per share | 0.06 | 0.04 | 0.06 | 0.08 | 0.09 | |
Operating cash flow per share | 0.2 | 0.28 | 0.2 | 0.36 | 0.37 | |
Free cash flow per share | 0.06 | 0.15 | 0.04 | 0.17 | 0.15 | |
Cash per share | 0.39 | 0.62 | 0.26 | 0.21 | 0.33 | |
Book value per share | 2.55 | 2.62 | 2.69 | 2.83 | 2.94 | |
Tangible book value per share | 2.55 | 2.62 | 1.91 | 2.04 | 2.16 | |
Share holders equity per share | 2.55 | 2.62 | 2.69 | 2.83 | 2.94 | |
Interest debt per share | 0.02 | 0.01 | 0.42 | 0.29 | 0.21 | |
Market cap | 287.4M | 368.59M | 379.8M | 258.69M | 302.17M | |
Enterprise value | 271.18M | 345.61M | 385.91M | 259.51M | 299.67M | |
P/E ratio | 29.47 | 60.74 | 40.75 | 22.16 | 21.73 | |
Price to sales ratio | 7.66 | 9.32 | 8.77 | 5.24 | 5.8 | |
POCF ratio | 37.4 | 35.12 | 49.82 | 18.73 | 21.35 | |
PFCF ratio | 136.08 | 63.39 | 245.82 | 40.38 | 52.87 | |
P/B Ratio | 2.96 | 3.68 | 3.63 | 2.38 | 2.67 | |
PTB ratio | 2.96 | 3.68 | 3.63 | 2.38 | 2.67 | |
EV to sales | 7.23 | 8.74 | 8.91 | 5.25 | 5.75 | |
Enterprise value over EBITDA | 65.64 | 51.96 | 46.27 | 24.19 | 25.21 | |
EV to operating cash flow | 35.29 | 32.93 | 50.62 | 18.79 | 21.18 | |
EV to free cash flow | 128.4 | 59.43 | 249.78 | 40.5 | 52.43 | |
Earnings yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0.01 | 0.02 | 0 | 0.02 | 0.02 | |
Debt to equity | 0.01 | 0.01 | 0.16 | 0.1 | 0.07 | |
Debt to assets | 0.01 | 0 | 0.11 | 0.07 | 0.05 | |
Net debt to EBITDA | -3.93 | -3.46 | 0.73 | 0.08 | -0.21 | |
Current ratio | 2.11 | 1.99 | 1.14 | 1.14 | 1.19 | |
Interest coverage | 110.44 | -39.47 | 145.05 | 17.75 | 21.96 | |
Income quality | 3.15 | 6.92 | 3.27 | 4.73 | 3.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.08 | 0 | 0.3 | 0 | 0.04 | |
Sales general and administrative to revenue | 0.49 | 0.53 | 0.51 | 0.51 | 0.49 | |
Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
Intangibles to total assets | 0 | 0 | 0.2 | 0.2 | 0.2 | |
Capex to operating cash flow | -0.73 | -0.45 | -0.8 | -0.54 | -0.6 | |
Capex to revenue | -0.15 | -0.12 | -0.14 | -0.15 | -0.16 | |
Capex to depreciation | -1.27 | -0.98 | -1.17 | -1.24 | -1.38 | |
Stock based compensation to revenue | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | |
Graham number | 1.92 | 1.53 | 1.91 | 2.2 | 2.45 | |
ROIC | 0.02 | 0.01 | 0.02 | 0.02 | 0.03 | |
Return on tangible assets | 0.02 | 0.01 | 0.02 | 0.02 | 0.03 | |
Graham Net | 0.22 | 0.34 | -0.46 | -0.44 | -0.31 | |
Working capital | 20.88M | 23.28M | 4.37M | 4.31M | 6.21M | |
Tangible asset value | 97.09M | 100.04M | 74.06M | 78.42M | 82.98M | |
Net current asset value | 19.79M | 22.11M | -8.66M | -4.73M | -2.62M | |
Invested capital | 0.01 | 0.01 | 0.16 | 0.1 | 0.07 | |
Average receivables | 15.24M | 15.86M | 17.62M | 18.42M | 18.14M | |
Average payables | 4.53M | 3.46M | 6.58M | 9.09M | 6.72M | |
Average inventory | 3.38M | 3.51M | 3.96M | 4.57M | 4.64M | |
Days sales outstanding | 36.96 | 37.13 | 39.32 | 32.66 | 31.68 | |
Days payables outstanding | 16.32 | 24.66 | 46.57 | 44.35 | 19.11 | |
Days of inventory on hand | 22.01 | 19.95 | 23.41 | 22.31 | 21.15 | |
Receivables turnover | 2.43 | 2.42 | 2.29 | 2.76 | 2.84 | |
Payables turnover | 5.51 | 3.65 | 1.93 | 2.03 | 4.71 | |
Inventory turnover | 4.09 | 4.51 | 3.84 | 4.03 | 4.25 | |
ROE | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | |
Capex per share | -0.15 | -0.12 | -0.16 | -0.19 | -0.22 |
VMD Frequently Asked Questions
What is Viemed Healthcare, Inc. stock symbol ?
Viemed Healthcare, Inc. is a US stock , located in Lafayette of La and trading under the symbol VMD
What is Viemed Healthcare, Inc. stock quote today ?
Viemed Healthcare, Inc. stock price is $9.38 today.
Is Viemed Healthcare, Inc. stock public?
Yes, Viemed Healthcare, Inc. is a publicly traded company.